Here’s a bold statement: Despite widespread concerns, a groundbreaking review has found no clear evidence linking paracetamol use during pregnancy to autism or ADHD in children. But here’s where it gets controversial—this finding challenges claims made by high-profile figures, including former US President Donald Trump, who suggested a causal link in 2025. Let’s dive into the details.
In a rapid umbrella review published in the BMJ on November 10, 2025 (https://www.bmj.com/content/391/bmj-2025-088141), researchers analyzed nine comprehensive reviews encompassing 40 studies. Six of these studies focused on autism, while 17 examined ADHD. The initial reviews hinted at a possible-to-strong association between maternal paracetamol use and these neurodevelopmental conditions in children. However—and this is the part most people miss—the authors of the rapid review expressed low to critically low confidence in these findings after deeper analysis.
Why the skepticism? While some studies reported positive associations, seven out of the nine reviews cautioned against jumping to conclusions. They cited critical issues like insufficient data, biases in primary studies, and unmeasured confounding factors. When researchers adjusted the data to account for familial influences—such as genetics, parental mental health, and socio-environmental factors—the supposed link between paracetamol and autism or ADHD either disappeared or weakened significantly.
This suggests that shared family traits, rather than paracetamol itself, may explain the observed risks. For instance, if a parent has a genetic predisposition to ADHD, their child might inherit this risk regardless of paracetamol use during pregnancy. And this is where it gets even more intriguing: the authors emphasize that stakeholders—from regulatory bodies to pregnant women—should be aware of the poor quality of existing reviews and the role of familial confounding in driving these associations.
But here’s the bigger issue: The lack of robust evidence on medication safety during pregnancy remains a critical, long-standing problem, rooted in historical underinvestment in women’s health research. This gap leaves expectant mothers and healthcare providers in a difficult position, often relying on incomplete or conflicting information.
The BMJ review was fast-tracked for publication following Trump’s controversial comments in September 2025, which sparked public alarm. Experts like Grainne McAlonan, a professor of translational neuroscience at King’s College London, welcomed the review, stating it carefully confirms that evidence does not clearly link paracetamol use in pregnancy to autism or ADHD.
Dimitrios Siassakos, a professor of obstetrics and gynecology at University College London, echoed this sentiment, noting that the high-quality methodology of the review aligns with global expert opinions. He emphasized that studies claiming a link are often confounded by shared family factors, such as genetics and lifestyle.
Claire Anderson, president of the Royal Pharmaceutical Society, reassured expectant parents that paracetamol remains a safe, first-line option for pain or fever during pregnancy when taken as directed. She encouraged anyone with concerns to consult a pharmacist or healthcare professional for reliable advice.
Now, here’s a thought-provoking question: Should we reevaluate how we approach medication safety research during pregnancy, especially given the historical neglect of women’s health? Share your thoughts in the comments—do you agree with the review’s conclusions, or do you think more research is needed? Let’s spark a conversation!
